Protara Therapeutics (TARA) Cash from Operations (2013 - 2026)

Protara Therapeutics' Cash from Operations history runs 14 years deep, the most recent figure standing at 21343000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 45.06% year-over-year to 21343000.0; the TTM figure through Mar 2026 stood at 62995000.0 (down 56.93% YoY), while the FY2025 annual figure was 56365000.0, down 57.41% from the prior year.
• Cash from Operations was 21343000.0 for Q1 2026 at Protara Therapeutics, down from 16950000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 5026000.0 in Q4 2022 to a low of 21343000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 10442941.18 across 5 years, with a median of 9408000.0 in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations surged 45.93% in 2022, then tumbled 83.64% in 2023.
• A 5-year view of Cash from Operations shows it stood at 5026000.0 in 2022, then tumbled by 73.1% to 8700000.0 in 2023, then dropped by 6.99% to 9308000.0 in 2024, then tumbled by 82.1% to 16950000.0 in 2025, then declined by 25.92% to 21343000.0 in 2026.
• The last three Cash from Operations figures came in at 21343000.0 (Q1 2026), 16950000.0 (Q4 2025), and 12452000.0 (Q3 2025), per Business Quant data.